Social media

Analysts, rejoice. Metys® offers predefined dashboards for quick answers and a powerful report builder for custom views – plus Excel integration for seamless workflows. It’s market intelligence, your way. Explore Mety...

Although advances in antiretroviral therapies are helping to curtail the HIV epidemic, there are limitations introduced by access and adherence. Find out what developers need to know when navigating these obstacles in th...

In settings with global HIV treatment disparities, the long-term success of antiretroviral interventions is jeopardised. Discover considerations for developing therapies that overcome obstacles in access, adherence and...

How to navigate EU MAA Regulations and Registration. Regulatory legislation in China differs substantially from that of the European Union. For Chinese biotech companies looking to enter the market it is critical to as...

Want to know what’s missing in next-gen drug delivery? In this article for BioPharm International, ICON’s Head of Regulatory CMC, Venkat Sunkara, outlines current product development trends happening in the world of bio...

By integrating molecular design, advanced delivery technologies and robust manufacturing practices, pharmaceutical companies can translate cutting-edge biopharmaceuticals into safe, effective therapies that reach patient...

USP compounding may be fast — but is it costing you quality, compliance, and insight? In this insightful session, our experts discussed: - Why GMP manufacturing offers a strategic edge in early phase trials - Real-worl...

While cardiovascular outcome trials are critical to demonstrating clinical value, they can also be complex and costly. Among the most challenging aspects are the people involved, from patients to investigators and commit...

Continuing our series of articles discussing managing risk for medical devices, ICON’s regulatory expert Jeremy Tinkler turns his focus on the biological risk estimate and looks into the logical basis for the use of comp...

The key to estimating biological risk in medical devices is establishing a good comparison. However, identifying the right comparison can be challenging. In the latest blog in our managing risk for medical devices series...

Our Creative & Digital Services and Global Medical Communications teams have been honoured for the ISMPP Academy Poster with an Rx Club Award of Excellence in the Posters/Display category. Congratulations for delivering ...

There is great excitement following the announcements by the FDA and EMA around streamlining the biosimilar trial process. They promise to reduce the burden on developers and therefore increase the number of more afford...